Sienna Biopharmaceuticals announces SNA-001 trial meets primary endpoint
Sienna Biopharmaceuticals announced positive topline results from its pivotal trial of SNA-001 in conjunction with an 810 nm Diode laser, involving 65 patients. SNA-001, a topical pre-treatment to standard laser hair removal, was studied in women and men with white, gray, blonde, light red and light brown hair. The data showed SNA-001 met the primary endpoint of non-inferiority in hair reduction. In additional analyses, SNA-001 was statistically superior compared to vehicle+Laser, demonstrating up to a 31% reduction of light hair from baseline. SNA-001 was also evaluated in conjunction with a 1064 Nd:YAG and 755 nm Alexandrite laser for the reduction of light hair, showing a significant reduction from baseline and providing a potential path to regulatory clearance. These results, however, were less differentiated from the vehicle+Laser group compared to the 810 nm Diode laser study results. A third and final pivotal trial of SNA-001 in acne was also completed, demonstrating SNA-001 was non-inferior to laser therapy and providing a potential path to regulatory clearance.